Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01856426 · ClinicalTrials.gov registry record · Phase 1
Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects
A Phase 1 study of Hepatitis C, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 5
- Study locations
NCT01856426 is a Phase 1 study of Hepatitis C that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 28 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT01856426, a Phase 1 study of Hepatitis C, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV gentotype-1 in chronically infected subjects and to further evaluate the safety profile of EDP239.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EDP239
Study Locations (5)
Other
- Investigative Site - Frankfurt
- Investigative Site - Hamburg
Florida
- Investigative Site - Miami
Texas
- Investigative Site - San Antonio
Utah
- Investigative Site - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01856426
The ClinicalTrials.gov registry entry for NCT01856426 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01856426 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT01856426 about?
NCT01856426 is a clinical study titled "Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects". The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV gentotype-1 in chronically infected subjects and to further evaluate the safety profile of EDP239.
What is the current status of trial NCT01856426?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2013-06. Estimated completion is 2015-10.
What conditions does trial NCT01856426 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT01856426?
The interventions under investigation include: Placebo (DRUG), EDP239 (DRUG).
Who is sponsoring clinical trial NCT01856426?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01856426 being conducted?
This trial has 5 study locations across Florida, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
COMPLETED · Phase 1
-
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 1
-
Open-Label Hepatic Impairment Study
COMPLETED · Phase 1
-
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
COMPLETED · Phase 1
-
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.